| Name | IRAK4-IN-1 |
| Description | IRAK4-IN-1 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM. |
| Animal Research | In the TLR driven in vivo model, female Lewis rats are dosed with either vehicle or IRAK4-IN-1 (Compound 23; 3, 10, 30, and 100 mg/kg; p.o.) dosed at 1 h prior to stimulation with Resiquimod, R848 (5 mg/kg, IP). At 1.5 h post R848 stimulation, blood samples are obtained from the animals and cytokine levels are measured. |
| In vitro | The in vitro metabolic stability profile of IRAK4-IN-1 was assessed, yielding an EC50 of 2300 nM in rat whole blood (RWB). |
| In vivo | Oral pharmacokinetic analyses of IRAK4-IN-1 indicate that it possesses a high bioavailability of 73%, along with low plasma clearance (Clp=22 mL/min/kg), which culminates in a stable half-life of 1.3 hours. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 1 mg/ml, Sonication is recommended.
H2O : < 0.1 mg/mL (insoluble)
|
| Keywords | IRAK4-IN-1 | inhibit | IRAK4 IN 1 | Inhibitor | IL-1R associated kinase | Interleukin-1 receptor associated kinase | IRAK4IN1 | IRAK-4-IN-1 | IRAK |
| Inhibitors Related | IRAK inhibitor 2 | IRAK inhibitor 1 | IRAK-1-4 Inhibitor I | IRAK-4 protein kinase inhibitor 2 | ANTHRAQUINONE-2-CARBOXYLIC ACID | Thalidomide 4-fluoride | IRAK4-IN-20 | GLPG2534 | Zabedosertib | Zimlovisertib | AS-2444697 | JH-X-119-01 |
| Related Compound Libraries | Highly Selective Inhibitor Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | Anti-Liver Cancer Compound Library |
United States
